Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23708726 | 0.88 | MALT1 (0.39) | — | |
| SCHEMBL29994713 | 0.88 | MALT1 (0.39) | — | |
| SCHEMBL23702779 | 0.88 | MALT1 (0.39) | — | |
| SCHEMBL23708175 | 0.86 | HCRTR1 (0.41) | HCRTR1HCRTR2PIK3CD | |
| SCHEMBL29994516 | 0.86 | HCRTR1 (0.41) | HCRTR1HCRTR2PIK3CD | |
| SCHEMBL26620528 | 0.86 | HCRTR1 (0.41) | HCRTR1HCRTR2PIK3CD | |
| SCHEMBL29935524 | 0.84 | RET (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL26620359 | 0.84 | RET (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL23703064 | 0.84 | RET (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL23702913 | 0.83 | HCRTR1 (0.40) | HCRTR1HCRTR2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| WO-2021154966-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | HCRTR1 894/4885HCRTR2 2355/4885PIK3CD 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.